COPD and Asthma Devices Market Size and Report 2023-2028

Comments · 239 Views

The global COPD and asthma devices market size reached US$ 43.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 60.4 Billion by 2028, exhibiting a growth rate (CAGR) of 5.31% during 2023-2028.

IMARC Group, a leading market research company, has recently releases report titled “COPD and Asthma Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global COPD and asthma devices market report, growth, share, size, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Industry Overview of COPD and Asthma Devices Market

COPD and asthma devices are specialized medical instruments crafted to support individuals grappling with respiratory ailments. These devices encompass inhalers, nebulizers, peak flow meters, and spacers, with inhalers being particularly effective at delivering medication directly into the lungs, offering rapid relief during asthma attacks or COPD exacerbations. Their role extends to symptom management, enhancement of lung function, alleviation of shortness of breath, reduction of wheezing, and relief from chest tightness. As a result, patients experience improved ease and comfort in breathing, leading to an overall enhancement in their quality of life. Furthermore, these devices are in growing demand globally because of their ability to facilitate improved airflow, heightened oxygen intake, and an overall boost in respiratory performance.

How Big Is the Animal Nutrition Chemicals Market?

The global COPD and asthma devices market size reached US$ 43.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 60.4 Billion by 2028, exhibiting a growth rate (CAGR) of 5.31% during 2023-2028.

Global Industry Trends and Drivers:

One of the primary drivers behind the increasing demand for effective respiratory management tools is the growing aging population and the higher incidence of respiratory disorders. These disorders are often attributed to factors such as escalating air pollution, widespread smoking, and shifts in lifestyle habits. Furthermore, manufacturers in the field are placing a strong emphasis on innovation, aiming to develop devices that excel in drug delivery, ease of use, and overall patient convenience. Additionally, the introduction of smart inhalers, incorporating digital technology, plays a significant role by enabling medication usage tracking and offering personalized feedback. Moreover, there is a notable shift towards home healthcare and the self-management of health conditions as a means to reduce the frequency of hospital visits. This trend is fueling the demand for portable and user-friendly COPD and asthma devices, as individuals seek more convenient and accessible ways to manage their health effectively.

What Is Included In Market Segmentation?

The report has been segmented the market into following categories:

Breakup by Product:

  • Inhalers
  • Drug Powdered Inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
  • Soft Mist Inhalers
  • Nebulizers
  • Compressor Nebulizers
  • Ultrasonic Nebulizers
  • Mesh Nebulizers 

Breakup by Indication:

  • Asthma
  • COPD

Breakup by Distribution Channel:

  • Retail Pharmacies
  • Hospitals
  • Online Pharmacies

 

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

The report provides a comprehensive analysis of the industry key players listed below:

Adherium Limited, Aristopharma Ltd., AstraZeneca PLC, Baxter International Inc., Boehringer Ingelheim International GmbH, Cohero Health Inc., Koninklijke Philips N.V., Omron Corporation, Pari Respiratory Equipment Inc., Recipharm AB and Verona Pharma plc.

Comments